This project has been flagged by a community member as inappropriate due to reason below.*

Survey

Slingshot members are conducting a survey! The topic is:

Quarterly Survey: Depression and Auvelity and Caplyta July 2023

Ticker(s): AXSM, ITCI

Who's being surveyed?

The survey includes 20 Psychiatrists.

Survey Questions
Q1.

How many patients with Major Depressive Disorder (MMD) do you have under your care?

Q2.

Are you familiar with Auvelity (dextromethorphan HBr-bupropion HCl) and data to date?

Q3.

Are you familiar with Caplyta (lumateperone) and data to date?

Q4.

How would you best describe your practice?

Q5.

What is your general view of Auvelity? What role, if any, do you see Auvelity playing in your practice? Please be specific.

Q6.

How much more difficult, if any, is it for you to prescribe Auvelity than Trintellix (i.e., the hoops that a patient has to jump through and the work you have to do to meet prior auth requirements and get through insurance)? Please explain.

Q7.

Do you expect the level of difficulty you face in prescribing Auvelity vs. Trintellix to improve significantly over the next 3-6 months?

Q8.

Why is that? Please be specific.

Q9.

How many MDD patients do you currently have on the following drugs:

  • Trintellix
  • Auvelity
  • Buproprion

Q10.

How many new MDD patients enter your practice over the course of a year?

Q11.

And of those new MDD patients, how many would you expect to try Auvelity (either immediately or after failing on another drug)?

Q12.

How many of your MDD patients are adequately controlled with their current drug regimen vs. inadequately controlled?

  • Adequately controlled
  • Inadequately controlled

Q13.

Of the [X] patients that are inadequately controlled, how many of these patients do you expect to try Auvelity on?

Q14.

How many patients did you start on Auvelity over the past 3 months?

Q15.

Of those new Auvelity starts, what percent (%) do you expect to stay on Auvelity for at least 6 months?

Q16.

Of the patients who initially respond well to Auvelity and stay on it past the first few months, what do you expect will be the total amount of time in months, on average, that they will end up staying on the drug?

Q17.

How many patients total do you expect to have on Auvelity at the following points in time:

  • 12/31/2023 (~6 months from now)
  • 6/30/2024 (~1 year from now)
  • 6/30/2025 (~2 years from now)
  • 6/30/2026 (~3 years from now)

Q18.

What is your general view of Caplyta? What role, if any, do you see Caplyta playing in your practice? Please be specific.

Q19.

How many patients did you start on Caplyta over the past 3 months?

Q20.

How many patients discontinued Capltya over the past 3 months?

Q21.

How many patients do you have on Caplyta today?

Q22.

How many patients total do you expect to have on Caplyta at the following points in time:

  • 12/31/2023 (~6 months from now)
  • 6/30/2024 (~1 year from now)
  • 6/30/2025 (~2 years from now)
  • 6/30/2026 (~3 years from now)

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.